Pharmacokinetics of the Melanocortin Type 1 Receptor Agonist PL8177 After Subcutaneous Administration [0.03%]
皮下给药后黑素皮质素1型受体激动剂PL8177的药物动力学
John Dodd,Robert Jordan,Marie Makhlina et al.
John Dodd et al.
Background and objective: PL8177 is a selective melanocortin 1 receptor agonist in development for the treatment of various immunologic and inflammatory conditions. Here we describe the pharmacokinetics of PL8177 after su...
Author's Reply to Petersen: "Differences in In Vitro Properties of Pancreatin Preparations for Pancreatic Exocrine Insufficiency as Marketed in Russia and CIS" [0.03%]
作者对Petersen的评论回复：“在俄罗斯和独联体市场销售的胰酶制剂对于胰腺外分泌不足的不同体外特性”
Igor V Maev,Yury A Kucheryavyy,Natalya B Gubergrits et al.
Igor V Maev et al.
Comment on: "Differences in In Vitro Properties of Pancreatin Preparations for Pancreatic Exocrine Insufficiency as Marketed in Russia and CIS" [0.03%]
评论：“在体外性质的差异俄罗斯和独联体市场销售的治疗胰腺外分泌不足的 pancreatin制剂”
请注意，原文是关于对某一特定科学研究或文章的评论，该研究比较了在俄罗斯和独联体市场上用于治疗胰腺外分泌功能不全的不同胰酶制剂（pancreatin）的体外性质。我的翻译主要侧重于传达这个意思，可能并不是一个可以直接使用的标题，因为它包含了“评论”这个词，这通常意味着是对某篇具体文章或研究结果的看法或评价。如果需要更正式或者简洁的标题，可以进一步调整。
Karl-Uwe Petersen
Karl-Uwe Petersen
Effects of Letermovir and/or Methylprednisolone Coadministration on Voriconazole Pharmacokinetics in Hematopoietic Stem Cell Transplantation: A Population Pharmacokinetic Study [0.03%]
Letermovir和/或甲基强的松龙联用对血液系统干细胞移植中伏立康唑药动学的影响：一项群体药动学研究
Kimitaka Suetsugu,Shota Muraki,Junshiro Fukumoto et al.
Kimitaka Suetsugu et al.
Objective: The aim of this study was to identify factors affecting blood concentrations of voriconazole following letermovir coadministration using population pharmacokinetic (PPK) analysis in allogeneic hematopoietic ste...
Prediction of Belimumab Pharmacokinetics in Chinese Pediatric Patients with Systemic Lupus Erythematosus [0.03%]
贝利木单抗在中国儿童系统性红斑狼疮患者中药代动力学的预测研究
Xuan Zhou,Tsung-I Lee,Min Zhu et al.
Xuan Zhou et al.
Background and objective: Intravenous (IV) belimumab is the first treatment approved for children ≥5 years of age with active autoantibody-positive systemic lupus erythematosus (SLE) in the USA, Europe, and Japan. Pharma...
Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy [0.03%]
患有转移性实体瘤并接受免疫治疗的患者的分离反应
Pauline Vaflard,Xavier Paoletti,Vincent Servois et al.
Pauline Vaflard et al.
Background: Immune checkpoint inhibitors have been demonstrated to improve overall survival. Atypical patterns of response have been reported, including dissociated response (DR). We evaluated the prevalence of DR. ...
The Safety of Agalsidase Alfa Enzyme Replacement Therapy in Canadian Patients with Fabry Disease Following Implementation of a Bioreactor Process [0.03%]
生物反应器工艺实施后加拿大Fabry疾病患者α-半乳糖苷酶替代治疗的安全性
Aneal Khan,Sandra M Sirrs,Daniel G Bichet et al.
Aneal Khan et al.
Background and objective: Fabry disease, an X-linked lysosomal storage disorder characterized by absent or reduced alpha-galactosidase activity, is a lifelong disease that impairs patients' quality of life. Patients with ...
Multicenter Study
Drugs in R&D. 2021 Dec;21(4):385-397. DOI:10.1007/s40268-021-00361-4 2021
Improvement of Intranasal Drug Delivery with Intravail® Alkylsaccharide Excipient as a Mucosal Absorption Enhancer Aiding in the Treatment of Conditions of the Central Nervous System [0.03%]
intravail®烷基糖苷增溶剂改进鼻给药递送作为黏膜吸收增强剂辅助中枢神经系统疾病的治疗
Adrian L Rabinowicz,Enrique Carrazana,Edward T Maggio
Adrian L Rabinowicz
Intranasal drug administration is a commonly used route for therapeutic formulations, but there may be challenges associated with a lack of absorption and bioavailability, as well as damage to mucosal tissue. To address these issues, potent...
Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment [0.03%]
阿哌沙班在轻度或中度肝功能不全患者中的药代动力学和药效学研究
Charles E Frost,Van Ly,Samira M Garonzik
Charles E Frost
Background: Hepatic impairment can impact apixaban pharmacokinetics and pharmacodynamics by decreasing cytochrome P450-mediated metabolism and factor X production. ...
Delayed Cutaneous Hypersensitivity Reaction to Vaxzevria (ChAdOx1-S) Vaccine against SARS-CoV-2 [0.03%]
对针对SARS-CoV-2的VAXZEVRIA（ChAdOx1-S）疫苗产生迟发型皮肤超敏反应
Rosanne Sprute,Sofie Schumacher,Martina Pauls et al.
Rosanne Sprute et al.
Recently, an increasing number of cases with delayed cutaneous reaction after immunization with mRNA-based vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been reported. This adverse reaction, which is con...